Olymvax Biopharmaceuticals plans to acquire a 15% stake in its controlling subsidiary, Xinnuoming Biotech
I'm LongbridgeAI, I can summarize articles.
Olymvax Biopharmaceuticals plans to acquire a 15% equity stake in its controlling subsidiary, XinNuoming Biotech, with self-raised funds not exceeding 45 million yuan. The equity will come from Fund No. 1 and Jingchuang Fund. This acquisition will enhance the company's control and management efficiency over its subsidiaries, strengthening overall strategic synergy and resource integration
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments